TLDR
- ARK Invest concentrated its buying activity on just three stocks last week: Figma, Arcturus Therapeutics, and 10x Genomics
- The investment firm purchased 337,381 Figma shares valued at more than $8.1 million on March 20
- Circle Internet Group saw significant selling pressure from ARK, with 45,998 shares sold across ARKK and ARKW for approximately $5.9 million
- Despite impressive 40% quarterly revenue expansion, Figma shares remain 83% below 2025 peak levels
- Additional sales included positions in Teradyne, Bullish, Guardant Health, and Butterfly Network
Cathie Wood’s ARK Invest demonstrated unusual restraint in its trading activity last week, limiting stock purchases to only three companies as equity markets continued their downward trajectory for a fourth consecutive week. Major indices all posted losses during this period.
The minimal buying activity represents a departure from Wood’s typical strategy of aggressive purchasing during market downturns, catching the attention of market observers and investors.
ARK’s investment activity centered on accumulating shares in Figma, Arcturus Therapeutics, and 10x Genomics. Simultaneously, the firm trimmed multiple positions, most notably divesting shares of Circle Internet Group, a cryptocurrency-focused enterprise.
Figma operates as a collaborative cloud-based design solution for creating digital interfaces, applications, and web properties. On March 20, ARK acquired 337,381 shares distributed between its ARKK and ARKW exchange-traded funds, representing an investment of $8,171,367.
Shares have plummeted 83% from their summer 2024 zenith, despite previously surging over 300% from the initial public offering price of $33. Remarkably, the company’s most recent quarterly report showed revenue advancing 40% year-over-year, an acceleration from the prior quarter’s 38% growth rate.
The company’s net dollar-retention metric reached 136%, indicating existing customers increased their platform spending by 36% compared to the same period last year. This marks the highest retention figure recorded in the past two years.
Wall Street analysts forecast revenue growth moderating to 30% in the current fiscal year before decelerating further to 20% in the following year. The company’s lack of consistent profitability has contributed to investor skepticism and share price pressure.
ARK Reduces Circle Internet Crypto Stake
In the cryptocurrency sector, ARK divested 45,998 shares of Circle Internet Group distributed across its ARKK and ARKW funds, totaling $5,902,923 in proceeds. The firm had been methodically reducing its Circle Internet holdings throughout the trading week.
Circle Internet serves as a major participant in the cryptocurrency infrastructure space, primarily recognized for its involvement with the USD Coin stablecoin.
Additional divestments included 19,206 Teradyne shares generating $5,807,894, alongside 103,379 Bullish shares for $4,093,808 and 9,621 Guardant Health shares for $857,038. ARK also offloaded 182,353 Butterfly Network shares, receiving $723,941.
Biotech Picks: Arcturus and 10x Genomics
Arcturus Therapeutics focuses on messenger RNA-based therapeutic development targeting uncommon respiratory conditions and liver disorders. ARK accumulated Arcturus shares during three separate trading sessions last week, concluding with a Friday purchase of 22,773 shares valued at $153,034 through its ARKG healthcare-focused ETF.
Arcturus has experienced consecutive annual revenue contractions for three years, with projections indicating further declines extending into 2026. Nevertheless, management recently announced an extension of the company’s financial runway through at least Q2 2028.
10x Genomics manufactures advanced life sciences instrumentation, featuring its Chromium system designed for single-cell genomic research applications. Last week, ARK purchased 192,658 shares distributed between ARKK and ARKG funds, totaling $3,541,054.
The biotechnology firm debuted on public markets at $38 per share and currently trades near half that valuation. The company has yet to achieve profitability, and management’s 2026 outlook suggests revenue contraction when excluding one-time licensing revenues from previous year patent settlements.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
